Sort   by:  
 Page size 
ProteomicsProteomic analysis of patients with advanced triple-negative breast cancer
In the later-line setting or for patients with PD-L1-negative tumors, immunotherapy-based regimens remain ineffective against advanced triple-negative breast cancer (TNBC). In this multicentered phase II trial (NCT04303741), 46 patients with pretreated advanced TNBC were enrolled to receive camreliz...
ORGANISM(S): Homo Sapiens 
2022-05-04 | PXD033655 |
ProteomicsTargeting RANKL-Independent Osteoclastogenesis Overcomes Denosumab Resistance in ER+ Breast Cancer Bone Metastasis
Bone metastasis remains a major cause of morbidity in ER+ breast cancer, with RANKL inhibitor resistance emerging as a critical clinical challenge. Nearly 40% of patients develop progressive skeletal lesions despite denosumab therapy, highlighting an urgent need to identify resistance mechanisms and...
ORGANISM(S): Homo Sapiens 
2026-01-29 | PXD073739 |
Sort   by:  
 Page size